EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A



Treatment and prevention of immunodeficiency virus infection by administration of non-pyrogenic derivatives of lipid A



Official Gazette of the United States Patent & Trademark Office Patents 1272(4), July 22



The present inventors have found that certain preparations containing LPS and/or lipid A variants, derivatives, and/or analogs demonstrate non-pyrogenic properties and exhibit anti-viral activities. In particular, non-pyrogenic preparations of LPS, lipid A, LPS antagonists and lipid A antagonists, and derivatives thereof induce beta chemokine secretion, such as MIP-1beta, but not proinflammatory cytokines, such as TNFalpha, IL-1beta and IL-6. Non-pyrogenic preparations of the invention have been demonstrated by the Applicant to suppress HIV replication in human peripheral blood monocytes, as described by way of example herein. The present invention provides preparations of LPS or lipid A variants, analogs and derivatives of decreased or absent pyrogenicity which can be used as therapeutics for the treatment or prevention of immunodeficiency virus infection and its consequences.

(PDF 0-2 workdays service: $29.90)

Accession: 035980025

Download citation: RISBibTeXText



Related references

Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. Aids 11(2): 157-162, 1997

Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. Aids Research and Human Retroviruses 14(9): 761-773, 1998

Administration of 9-(2-(phosphonomethoxy)propyl)adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Research and Human Retroviruses 14(9): 761-773, 1998

Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. Centers for Disease Control and Prevention. Mmwr. Recommendations and Reports 48(Rr-13): 1-27, 29-31, 2000

Administration of zidovudine for treatment of infection due to human immunodeficiency virus. Reviews of Infectious Diseases 13(1): 186-187, 1991

Treatment and prevention of HIV infection by administration of derivatives of human chorionic gonadotropin. Official Gazette of the United States Patent & Trademark Office Patents 1252(3), Nov 20, 2001

Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus. Journal of Virological Methods 17(1-2): 45-53, 1987

Diffuse cutaneous dissemination of visceral leishmaniasis during human immunodeficiency virus (HIV) infection, despite negligible immunodeficiency: repeated failure of liposomal amphotericin B administration, followed by successful long-term pentamidine and paromomycin administration. International Journal of Antimicrobial Agents 31(6): 590-592, 2008

Update on Pediatric Human Immunodeficiency Virus Infection: Paradigms in Treatment and Prevention. Advances in Pediatrics 63(1): 147-171, 2016

A review of the epidemiology, prevention and treatment of human immunodeficiency virus infection in Nigeria. Brazilian Journal of Infectious Diseases 11(6): 579-590, 2008

Treatment and prevention of opportunistic infections in patients with human immunodeficiency virus infection. Advances in Internal Medicine 41: 31-84, 1996

Pulmonary oxygen toxicity in rats: prevention by pyrogenic diphosphoryl lipid A and potentiation by nontoxic monophosphoryl lipid A and lipid X. Research Communications in Chemical Pathology and Pharmacology 62(2): 221-234, 1988

Meta-analytical studies on the epidemiology, prevention, and treatment of human immunodeficiency virus infection. Infectious Disease Clinics of North America 23(2): 295-308, 2009

Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus infection. Official Gazette of the United States Patent & Trademark Office Patents 1252(3), Nov 20, 2001

Effectiveness of postinoculation -9- adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. Journal of Virology 72(5): 4265-4273, March, 1998